Nature Communications (Sep 2021)
Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer
- Jing Li,
- Shunya Ohmura,
- Aruna Marchetto,
- Martin F. Orth,
- Roland Imle,
- Marlene Dallmayer,
- Julian Musa,
- Maximilian M. L. Knott,
- Tilman L. B. Hölting,
- Stefanie Stein,
- Cornelius M. Funk,
- Ana Sastre,
- Javier Alonso,
- Felix Bestvater,
- Merve Kasan,
- Laura Romero-Pérez,
- Wolfgang Hartmann,
- Andreas Ranft,
- Ana Banito,
- Uta Dirksen,
- Thomas Kirchner,
- Florencia Cidre-Aranaz,
- Thomas G. P. Grünewald
Affiliations
- Jing Li
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Shunya Ohmura
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Aruna Marchetto
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Martin F. Orth
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Roland Imle
- Hopp Children’s Cancer Center (KiTZ)
- Marlene Dallmayer
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Julian Musa
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Maximilian M. L. Knott
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Tilman L. B. Hölting
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Stefanie Stein
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Cornelius M. Funk
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Ana Sastre
- Unidad Hemato-oncología Pediátrica, Hospital Infantil Universitario La Paz
- Javier Alonso
- Pediatric Solid Tumour Laboratory, Institute of Rare Diseases Research (IIER), Instituto de Salud Carlos III
- Felix Bestvater
- Light Microscopy Facility, German Cancer Research Center (DKFZ)
- Merve Kasan
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Laura Romero-Pérez
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Wolfgang Hartmann
- Division of Translational Pathology, Gerhard-Domagk-Institute for Pathology, University Hospital Münster
- Andreas Ranft
- Pediatrics III, AYA Unit, West German Cancer Centre, University Hospital Essen
- Ana Banito
- Hopp Children’s Cancer Center (KiTZ)
- Uta Dirksen
- Pediatrics III, AYA Unit, West German Cancer Centre, University Hospital Essen
- Thomas Kirchner
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Florencia Cidre-Aranaz
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Thomas G. P. Grünewald
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- DOI
- https://doi.org/10.1038/s41467-021-25553-z
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 12
Abstract
In this study, the authors show that that oncogenic hijacking of PRC1 sensitizes genomically stable Ewing sarcoma cells for PLK1 inhibition alone or in synergy with a microtubule-destabilizing drug via induction of cytokinesis defects, rendering PRC1 a promising, broadly applicable predictive biomarker
